Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

NCT03469349 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Diseases

Interventions

DRUG: Actovegin
DRUG: Placebo

Sponsor

Takeda